NEWS

Written by: Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates Download Here For patients with Non‐Small Cell Lung Cancer (NSCLC) that have sensitizing epidermal growth factor receptor (EGFR) mutations (most commonly exon 19 deletions or exon 21 L858R mutations) appropriate for first‐line treatment with an EGFR inhibitor, osimertinib (Tagrisso) has a clear progression free survival […]

Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates Download Here Description: Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis.  The 17p deletion is found 3‐10% of the time at diagnosis, but 30‐ 50% at relapse.   Testing rates at diagnosis and especially relapse are low.  Venetoclax is […]

David Stanley recently contributed in the Modern Medicine Networking on how, "PBMs Pay Less Each Year While Prices Go Up". "Most of you are familiar with Medicare Part D direct and indirect remuneration (DIR) fees and know them as just another headache that comes along with your PBM contract. In a nutshell, when a DIR […]

NCODA has uploaded the updated patient survey in both English and Spanish in the member portal. Click here for English version. Click here for Spanish version.

This year’s Spring Summit in Chicago on March 2nd – 4th will cover a variety of topics such as: Sharing Value: NCODA Activities, Tools, Goals, ResourcesDefining EffectivenessAudits – Let’s hear from the auditorsIOD Accounting – Making Sense of the CentsMACRA/MIPS – What it means to you! Sybil GreenThe Problems with SPs and PBMs! War stories […]

As the use of oral oncolytics increases, cancer programs face a number of challenges to ensure high-quality care for cancer patients. There are significant variations in how cancer programs are treating patients with oral oncolytics. Arizona Oncology, a founding member of NCODA, is highlighted within:

Syracuse, NY, October 31, 2016 – NCODA (National Community Oncology Dispensing Association, Inc.) would like to highlight a major victory in the treatment landscape for oncology patients. On Thursday, October 27, CVS Health announced it had reversed its decision to limit Medicare Part D access away from oncology practices with in office dispensing as of […]

MISSION STATEMENT/PHILOPSOPHY: The physicians, staff and management of Utah Cancer Specialists are dedicated to the diagnosis, treatment and management of all forms of cancer and blood related diseases. UCS is dedicated to helping people with these diseases achieve optimum health and quality of life through excellence in the delivery of compassionate medical care. UCS understands […]

Mission Statement: Meeting and exceeding the needs of our patients is our primary goal. We recognize that each patient is an individual with unique needs. Our staff is dedicated to the fight against cancer and providing A New Way of Caring. Locations: Virginia Cancer Specialists has locations in Fairfax, Alexandria, Arlington, Fair Oaks, Gainesville, Loudon, […]

NCODA practices have successfully collaborated with another regional payor for the ability to go beyond the first fill! That brings the number of payers that have now collaborated with NCODA practices up to four! Several NCODA practices are currently in payor discussions!

WASHINGTON — The federal Medicare program and private health insurers waste nearly $3 billion every year buying cancer medicines that are thrown out because many drug makers distribute the drugs only in vials that hold too much for most patients, a group of cancer researchers has found. Click here for the New York Times Article… […]

Oral oncolytic regimens have many benefits; however, patients can encounter barriers (e.g., institutional, socioeconomic, treatment) that can hinder their ability to take their medication as prescribed. Patients with metastatic colorectal cancer (mCRC) face complex dosing schedules that challenge adherence. When patients take oral therapies at home, healthcare professionals (HCPs) can use tools to empower their […]